Effect of PVP-K30 on complexation and dissolution rate of nevirapine-β-cyclodextrin complexes

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 2, Issue 4, 2010, Pages 169-176

  Lokamatha, K M ^a   Bharathi, A ^a   Shanta Kumar, S M ^a   Rama Rao, N ^b  

^a VL College of Pharmacy   (India)

^b CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

cyclodextrin; Antiretroviral; Nevirapine; Polyvinylpyrrolidone K30; Solid complexes

Indexed keywords

BETA CYCLODEXTRIN; NEVIRAPINE; POLYMER; POVIDONE; POVIDONE K30; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; PH; SCANNING ELECTRON MICROSCOPY; STOMACH PH; X RAY DIFFRACTION;

EID: 83455172298     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Davis ME, Brewster ME. Cyclodextrin based pharmaceutics: Past, present and future. Nat Rev Drug Discovery 2004; 3:1023-1035.
2. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 2002; 231:131-144.
3. Serajuddin ATM. Solid dispersions of poorly water soluble drugs: Early promises, subsequent problems and recent breakthroughs. J Pharm Sci 1999;88(10):1058-1066.
4. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007; 329:1-11.
5. Nelson M, Waters L, John L. Non-nucleoside reverse transcriptase inhibitors: a review. Int J Clin Pract 2007; 61(1):105-118.
6. Kusum VD, Roopa SP. Antiretrovirals: Need for an Effective Drug Delivery. Ind J Pharm Sci 2006; 68(1):1-6.
7. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1(1):85-96.
8. Lamson MJ, Sabo JP, MacGregor TR, Pav TW, Rowland L, Hawi A. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos 1995; 20:285-291.
9. Szejtli J, Smolen F, Ball L, Eds., Molecular Entrapment and Release Properties of Drugs by Cyclodextrins and Congeners. Controlled Drug Bioavailability. 1985; 5:365-420.
10. Pitha, Szente L, Bruck SD, Eds., Molecular Encapsulation by Cyclodextrins and Congeners. Controlled Drug Delivery, 1983; 1:125-148.
11. Loftsson T. Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers. Pharmazie 1998; 53:733-740.
12. Loftsson T, Masson M, Sigurjonsdottir JF. Methods to enhance the complexation efficiency of cyclodextrins. STP Pharma Sci 1999; 9:237-42.
13. Siguroardottir AM, Loftsson T. The effect of polyvinylpyrrolidone on cyclodextrin complexation of hydrocortisone and its diffusion through hairless mouse skin. Int J Pharm 1995; 126:73-78.
14. Loftsson T, Masson M. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J Drug Del Sci Tech 2004; 14:35-43.
15. Higuchi T, Connors KA. Phase Solubility Techniques. Adv Anal Chem Instrum 1965; 4:117-212.
16. Hawi A, Bell G. Preformulation studies of nevirapine, a reverse transcriptase inhibitor. Pharm Res 1994;11(Suppl):236.
17. Mura P, Faucci, MT, Manderioli A, Bramanti G. Multicomponent system of econazole with hydroxyacids and cyclodextrins. J Incl Phenom Macro 2001; 39:131-138.
18. Macha S, Yong C, MacGregor T, Castles M, Quinson A, Rouyrre N, Wilding I. Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract. J Clin Pharmacol 2009; 49:1417-1425.
19. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol 1975; 27:48-49.